Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Agomab Therapeutics NV today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares (“ADSs”)
-
Agomab today announced the pricing of its initial public offering of 12,500,000 ADSs representing 12,500,000 of its common shares.
-
Agomab today announced the launch of its initial public offering of 12,500,000 ADSs pursuant to a registration statement filed with the SEC.
-
Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.
-
Agomab announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA1 Phase 2a clinical trial for ontunisertib (AGMB-129)
-
Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal...